| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 64 | 38.6x | 17.8x | Around median | |
Growth | 42 | 8.5% | 7.1% | Around median | |
Quality | 62 | 2.3% | 4.5% | Around median | |
Safety | 81 | — | 2.6x | Top tier | |
Capital Return | 90 | — | 2.12% | Top tier | |
Momentum | 29 | 8.8% | 2.9% | Bottom tier | |
Sentiment | 41 | 6 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Omnicell provides medication management systems and technologies to healthcare institutions and aims to automate dispensing, inventory, and pharmacy workflows. Its revenue model consists of sales of connected devices, led by the Titan XT automated dispensing system, and recurring services that include specialty pharmacy, maintenance and support, and software; OmniSphere is also the cloud platform that brings together devices, data, and workflows and enables the addition of analytics and AI-powered capabilities.
In Q2 of fiscal year 2026, revenue reached $312 million, at the high end of the previous guidance range. Products contributed $175 million, or about 56% of revenue, while services revenue reached $137 million, or about 44%, supported by specialty pharmacy, maintenance and support, and software. Adjusted gross margin was 50%, adjusted earnings before interest, taxes, depreciation, and amortization were $67 million, and adjusted earnings per share were $0.94, while generally accepted accounting principles earnings per share were $0.52 versus $0.12 in the corresponding period.
Q2 fiscal year 2026 results included a nonrecurring customs refund of $15 million; without it, adjusted earnings before interest, taxes, depreciation, and amortization would have been $52 million, while remaining above the midpoint of previous guidance. The company ended the quarter with cash and cash equivalents of $292 million and free cash flow of $56 million, both of which included the impact of the customs refund.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus rates OMCL as “Neutral,” with an average price target of $57.50 and a range of $50 to $65; the average is about 4.5% above the 52-week range high of $55, while the highest target exceeds that high by about 18%. No published price-to-earnings ratio is available in the data, despite reported net income of $20.4 million and earnings per share of about $0.445 during the 2026 trailing-twelve-month period, so the valuation remains less clear, and the target range should be weighed against the neutral consensus, bookings volatility, and margin pressures.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Omnicell trades on NASDAQ under the ticker OMCL, and its market capitalization stated in the data is $1.6 billion. The company generates revenue from connected medication management systems and recurring services, including specialty pharmacy, maintenance and support, and software. In Q2 fiscal year 2026, product revenue was $175 million and services revenue was $137 million, out of a total of $312 million.
Titan XT is the device platform for automated dispensing systems and was built on the experience of the previous XT platform. OmniSphere is the cloud hub on which software and workflows are built, and the company plans to connect other products and devices to it over time. Titan XT remained on track to ship in the second half of fiscal year 2026, while OmniSphere ADS is targeting general availability in the first half of fiscal year 2027.
Generally accepted accounting principles earnings per share were $0.52 in Q2 fiscal year 2026, versus $0.12 in the corresponding period. Adjusted earnings per share were also $0.94, and adjusted earnings before interest, taxes, depreciation, and amortization were $67 million. The results included a nonrecurring customs refund of $15 million, and adjusted earnings before interest, taxes, depreciation, and amortization would have been $52 million after excluding it.
The company set expected product bookings at $425–$560 million in fiscal year 2026, keeping the high end unchanged and lowering the low end. Management explained that medium-sized and large deals go through capital approvals and clinical, technical, and contractual evaluations that may take several quarters or years. Therefore, the wider range is tied to the timing of decisions before December 31, 2026, while management said the opportunity pipeline at the end of Q2 fiscal year 2026 was meaningfully larger than in recent years.
Omnicell estimated that the supply and demand imbalance in memory chips would add $6 million to costs in the second half of fiscal year 2026. This represents an increase of approximately fivefold compared with the cost level at the beginning of fiscal year 2026. The company expects this factor to reduce consolidated gross margin by about 50 basis points and product margin by about 80 basis points for the full fiscal year 2026.
In Q2 fiscal year 2026, the company recorded its first competitive conversion to Titan XT during the year with a healthcare system in the southeastern United States. The selection included Titan XT, OmniSphere, AWS, and intravenous solution workflows, while the flexible leasing option also helped complete the deal. In addition, healthcare systems in North Carolina, Texas, and Arizona selected Titan XT with central pharmacy and inventory optimization solutions.
